2,044
Views
11
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: MEDICAL ONCOLOGY

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials

ORCID Icon, , , , , & show all
Pages 872-879 | Received 29 Nov 2018, Accepted 06 Feb 2019, Published online: 04 Mar 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Bader Alshamsan, Ahmad Badran, Aisha Alshibany, Fatma Maraiki, Mahmoud A Elshenawy, Tusneem Elhassan & Jean Paul Atallah. (2021) Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma. Cancer Management and Research 13, pages 6755-6766.
Read now

Articles from other publishers (10)

Bei Chen, Xin Zhao, Xiying Li, Jun Liu & Juyu Tang. (2022) Fatal heart disease in patients with bone and soft tissue sarcoma. Frontiers in Cardiovascular Medicine 9.
Crossref
Marissa A. Just, David Van Mater & Lars M. Wagner. (2021) Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer 68:8.
Crossref
Andrew J. Bellantoni & Lars M. Wagner. (2021) Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors. Cancers 13:14, pages 3531.
Crossref
Neeta Somaiah, Brian Andrew Van Tine, Amy E. Wahlquist, Mohammed M. Milhem, Elizabeth G. Hill, Elizabeth Garrett‐Mayer, Kent E. Armeson, Scott M. Schuetze, Christian F. Meyer, Daniel Y. Reuben, Anthony D. Elias, William L. Read, Sant P. Chawla & Andrew S. Kraft. (2020) A randomized, open‐label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft‐tissue sarcoma. Cancer 127:6, pages 894-904.
Crossref
Jane Koo, Jessica Knight-Perry, Csaba Galambos, Lorna P. Browne & Carrye R. Cost. (2021) Pediatric Metastatic Cardiac Angiosarcoma Successfully Treated With Multimodal Therapy: Case Report and Review of Literature. Journal of Pediatric Hematology/Oncology 43:2, pages e203-e206.
Crossref
Yoshihiro Nishida, Hiroshi Urakawa, Robert Nakayama, Eisuke Kobayashi, Toshifumi Ozaki, Keisuke Ae, Yoshihiro Matsumoto, Hiroyuki Tsuchiya, Takahiro Goto, Hiroaki Hiraga, Norifumi Naka, Shunji Takahashi, Yuichi Ando, Masahiko Ando, Yachiyo Kuwatsuka, Shunsuke Hamada, Takafumi Ueda & Akira Kawai. (2020) Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors . International Journal of Cancer 148:1, pages 140-149.
Crossref
Mustafa Karaağaç, Yasin Sezgin, Melek Karakurt Eryılmaz, Murat Araz, Muhammet Ali Kaplan & Mehmet Artaç. (2020) The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort. Journal of Oncology Pharmacy Practice 26:7, pages 1657-1666.
Crossref
Mustafa Karaağaç & Melek Karakurt Eryılmaz. (2019) Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature. Journal of Oncology Pharmacy Practice 26:3, pages 768-774.
Crossref
Adrienne T. Black, Daniel Zinkovsky, Shelly Ray & Sidhartha D. Ray. 2020. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 495 506 .
Alex T. J. Lee, Robin L. Jones & Paul H. Huang. (2019) Pazopanib in advanced soft tissue sarcomas. Signal Transduction and Targeted Therapy 4:1.
Crossref